With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.391604-55-0,2-(2,4-Difluorophenyl)pyridine,as a common compound, the synthetic route is as follows.
In a Schlenk’s flask were placed iridium(III) trichloride hydrate (500 mg, 1.42 mmol, 1 equivalent) and silver(I) trifluoromethanesulfonate (1.09 g, 4.26 mmol, 3.0 equivalents), and the interior of the flask was substituted with nitrogen. There were added 2-(2,4-difluorophenyl)pyridine (2 mL, s/s=4) and water (1 mL, s/s=2), and the mixture was heated at 200C on an oil bath with stirring for 3 hours. The resulting black mixture was evaporated to dryness, and the residue was purified by silica gel column chromatography (eluent: dichloromethane). The column fractions were condensed, and recrystallized from hexane/dichloromethane to give 571 mg of the title compound (5-6) as yellow green powder in 52.7% yield. NMR data of the product was identical to that of Example 12.
391604-55-0, 391604-55-0 2-(2,4-Difluorophenyl)pyridine 11263359, acatalyst-ligand compound, is more and more widely used in various fields.
Reference£º
Patent; TAKASAGO INTERNATIONAL CORPORATION; WO2004/43974; (2004); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI